Early Access — free while we kick the tires
EdgarHawk

ALNY ALNYLAM PHARMACEUTICALS, INC. Insider Trading

Latest: Director Sold $1.1M of Shares · Jun 2026
1 filing analyzed · Latest 2026-06-03
Insider buys
0
Insider sells
1
Unique insiders
1
Direction
Net selling
June 2026
2026-06-03
medium
David E I Pyott Sell
3,830 shares
$1,145,853
@ $299.18
Significance 5/10

Director David E I Pyott sells 3,830 shares at avg $299.18 under pre-arranged 10b5-1 plan; retains 1,582 shares post-transaction.

Director David E I Pyott executed 5 separate sales totaling 3,830 shares for $1,145,852.75 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-12, reducing his non-derivative holdings by 70.8% from 5,412 shares to 1,582 shares. The sales were executed at prices ranging from $297.71 to $302.65, yielding a blended average price of $299.18, against a current market price of $292.58. Because this transaction is governed by a scheduled 10b5-1 plan rather than discretionary choice, the filing reflects automatic execution rather than a market-timing decision by the insider. The company's fundamentals show strong growth (annual revenue growth of 65.2%, net income of $251.1M on $1.2B quarterly revenue) and a market cap of $38.8B, though the stock is currently -41.0% from its 52-week high of $495.55. His prior sales at ALNY show mixed timing outcomes (the most recent sale on 2025-03-24 saw a 30-day decline of -19.1%), though this specific filing represents scheduled divestiture rather than discretionary positioning.

Get alerts for ALNY

Add ALNY to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.

Sign up — free during early access